Showing results (1311-1320 of 1,385) with videos related to

Sort By:
Pageof 139
Biorxiv : the Preprint Server for Biology|June 25, 2020
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodiesChristopher O Barnes, Anthony P West, Kathryn E Huey-Tubman, et al.
JAMA|March 4, 2008
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett, Samuel M Silver, Benjamin Djulbegovic, et al.
Current Biology : CB|September 23, 2015
Rapid tree carbon stock recovery in managed Amazonian forestsErvan Rutishauser, Bruno Hérault, Christopher Baraloto, et al.
Biorxiv : the Preprint Server for Biology|April 5, 2022
Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal modelsAlexander A Cohen, Neeltje van Doremalen, Allison J Greaney, et al.
European Radiology|March 7, 2022
Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensusDoenja M J Lambregts, Nino Bogveradze, Lennart K Blomqvist, et al.
Cell|July 10, 2020
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesChristopher O Barnes, Anthony P West, Kathryn E Huey-Tubman, et al.
Science (New York, N.Y.)|February 12, 2026
More than mitigation: The role of forests in climate adaptationJosephine Elena Reek, Constantin M Zohner, Gabriel Reuben Smith, et al.
Gut|June 28, 2012
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancerYonghui Wu, Heike Grabsch, Tatiana Ivanova, et al.
Science (New York, N.Y.)|July 20, 2022
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal modelsAlexander A Cohen, Neeltje van Doremalen, Allison J Greaney, et al.
Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.
Pageof 139